Arla unveils protein-based ingredient beverage to support health of people with chronic kidney disease

DENMARK – Centre for Disease Control and Prevention reveals that more than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have Chronic Kidney Disease (CKD) and they require special types of foods and drinks that deliver health benefits.

Responding to this need, Arla Foods Ingredients, a subsidiary of Danish dairy cooperative Arla, has released two new protein-based ingredient beverage prototypes.

The 7% protein ready-to-drink beverage and a 21% protein shot beverage options under the Lacprodan® BLG-100 brand have a low viscosity and a minimal phosphorus content compared to most alternatives available on the market.

The RTD drinks designed with a focus on nutrition also feature 7% protein, 10% fat, and 20% carbohydrates to help people transitioning from stage 1 to stage 5 of chronic kidney disease and who are not on dialysis treatment.

In addition, the high-protein shot solution is formulated specifically for the dietary management of people with CKD on dialysis who have limited fluid intake or require high amounts of protein.

This application is ideal to help control phosphorus levels in the body and, at the same time, incorporate high-quality protein into the diet.

Mads Dyrvig, Head of Health and Performance Sales Development, said: “While minerals are essential for life, too much is a serious problem if the body has reduced ability to remove them.

The nutritional challenge for someone with CKD is that many of the foods we eat, such as meat and dairy, are rich in phosphorus. People diagnosed with CKD are advised to reduce dietary protein intake significantly.”

He explained that the dilemma that presents itself is that, for a patient with CKD, is the accumulation of phosphorus in the body that increases the risk of heart attack and stroke.

This can lead to cardiovascular disease; the alternative is to reduce protein intake and gradually lose a significant amount of muscle mass (muscle atrophy).

Both conditions increase the risk of mortality, and muscle atrophy also decreases the quality of life of patients.

Most commercially available oral nutritional supplements are relatively high in minerals, including excessive phosphorus, which is part of the minerals that the CDK people should avoid, including also potassium, sodium, and calcium.

Dyrvig noted that the 100% pure BLG ingredient is rich in essential amino acids and leucine, so it contains high-quality protein that meets the nutritional needs of CKD and ESRD patients.

Furthermore, it is extremely low in phosphorous, and therefore It is an excellent solution for medical nutrition products as it facilitates protein supplementation and meets low mineral intake requirements.

This year, Arla Foods Ingredients’ novel food application for Lacprodan® BLG-100 received a positive opinion from the European Food Safety Authority (EFSA) confirming that it is safe and suitable for use in foods in the European Union.

 Additionally, Lacprodan® BLG-100 recently received the Breakthrough Award 2022 Dairy Ingredient Innovation Award from the American Dairy Products Institute (ADPI).

Liked this article? Subscribe to Food Business Africa News, our regular email newsletters with the latest news insights from Africa and the World’s food and agro-industry. SUBSCRIBE HERE.

More News Articles

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.